Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to a report published online today in Science Translational Medicine. The results show promise for developing therapies against the virus, which causes hemorrhagic fever with human case fatality rates as high as 90 percent.
According to first author James Pettitt of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the research team previously demonstrated that the treatment—known as MB-003—protected 100 percent of non-human primates when given one hour after Ebola exposure. Two-thirds of the animals were protected when treated 48 hours after exposure.
In the current study, 43 percent of infected non-human primates recovered after receiving the treatment intravenously 104 to 120 hours after infection. The experimental design differed significantly from the team's earlier work—this time, infected animals were not treated until they developed measurable symptoms of disease.
Ebola virus has been responsible for numerous deaths in Africa over the past several years. In addition to being a global health concern, the virus also is considered a potential biological threat agent.
"By requiring both a documentable fever and a positive diagnostic assay result for Ebola infection before initiating treatment in these animals, we were able to use MB-003 as a true therapeutic countermeasure," said senior author Gene Olinger, Ph.D., of USAMRIID. "These initial results push the threshold of MB-003 from post-exposure prophylaxis to treating verified illness."
According to the scientists, Ebola virus replicates quickly to very high levels, thus overwhelming the host's ability to fight off the infection. MB-003 is a "cocktail" of monoclonal antibodies that help bind to and inactivate the virus. In addition, said Pettitt, the antibodies recognize infected cells and trigger the immune system to kill them off. No side effects of the antibodies were observed in the surviving animals.
MB-003 was developed through a decade-long collaborative effort between private industry and the U.S. government, with funding from the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health (NIH), and the Defense Threat Reduction Agency (DTRA).
"With no vaccines or therapeutics currently licensed to treat or prevent Ebola virus, MB-003 is a promising candidate for continued development," said collaborator Larry Zeitlin, Ph.D., president of Mapp Biopharmaceutical in San Diego, California.
MB-003 is manufactured in a plant-based system by Kentucky BioProcessing in Owensboro, Kentucky. According to Barry Bratcher, the company's chief operating officer, the plant-based system allows for considerable efficacy while KBP's automated facility keeps MB-003 cost-effective and cuts down on the production time required.
"Our facility can produce these proteins in two weeks at a substantial reduction in cost to other production methods," said Bratcher. "This advanced method of manufacturing allows us to address needs quickly and inexpensively."
Zeitlin said Mapp recently announced formation of a joint venture between LeafBio (Mapp's commercialization arm) and Defyrus of Toronto, Canada, to consolidate their antibody programs. He said the relationship will streamline development of the most potent anti-filovirus products.
According to Zeitlin, the next step in the drug development process would be to more extensively test the safety of the antibodies in animals. Once that is established, the safety of the antibodies would need to be assessed in human volunteers. Ultimately, a large efficacy study in non-human primates and a larger safety study in humans would be required for Food and Drug Administration (FDA) licensure of the product.
Explore further: Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
More information: J. Pettitt, L. Zeitlin, D. H. Kim, C. Working, J. C. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. H. Pauly, K. J. Whaley, M. F. Ingram, A. Zovanyi, M. Heinrich, A. Piper, J. Zelko, G. G. Olinger. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013)
Medical Xpress on facebook
Related Stories
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
Oct 15, 2012
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.
Scientists identify protective role for antibodies in Ebola vaccine study
Jan 14, 2013
Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.
Post-exposure antibody treatment protects primates from Ebola, Marburg viruses
Mar 13, 2012
Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment ...
Ebola virus uses a protein decoy to subvert the host immune response
Dec 13, 2012
In a study published today in the Open Access journal PLOS Pathogens, researchers at Emory University have discovered a potentially important mechanism by which the Ebola virus alters and evades the immune response of its ...
Scientists reveal how deadly Ebola virus assembles
Aug 15, 2013
Scientists at The Scripps Research Institute (TSRI) have discovered the molecular mechanism by which the deadly Ebola virus assembles, providing potential new drug targets. Surprisingly, the study showed ...
Recommended for you
Rare polio outbreak spreads to Israel's north
3 hours ago
Israel's president is urging the country's children to get polio boosters after a rare outbreak of the virus spread to the north of the country.
New strategy tests for lethal stage of TB in Asia
6 hours ago
More than 20,000 people in Pakistan are being tested for the potentially deadly stage of tuberculosis using a new strategy developed at UC Davis Health System to effectively detect the disease in children for the first time.
Infection during newborn's first week of life associated with bacterial infection in the mother
20 hours ago
Early-onset neonatal infection, defined as infection in the first 7 days of life, is associated with maternal infection and colonization, a systematic review and meta-analysis by Grace Chan (Johns Hopkins School of Public ...
MERS case in Qatar
22 hours ago
Health authorities in Qatar on Tuesday announced the first case of MERS coronavirus in the Gulf state, with a 59-year-old man infected.
Spinal radiosurgery ups risk of vertebral fracture
Aug 20, 2013
(HealthDay)—Vertebral compression fracture (VCF) is a common adverse effect in patients receiving spine stereotactic body radiotherapy (SBRT), according to research published online Aug. 19 in the Journal of ...
Salmonella outbreak linked to NM poultry hatchery
Aug 19, 2013
(AP)—State health officials say a national outbreak of salmonella has been linked to an eastern New Mexico hatchery that sells live baby poultry by mail and supplies them to feed stores.
User comments
© Medical Xpress 2011-2013, Phys.org network
Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to a report published online today in Science Translational Medicine. The results show promise for developing therapies against the virus, which causes hemorrhagic fever with human case fatality rates as high as 90 percent.
According to first author James Pettitt of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the research team previously demonstrated that the treatment—known as MB-003—protected 100 percent of non-human primates when given one hour after Ebola exposure. Two-thirds of the animals were protected when treated 48 hours after exposure.
In the current study, 43 percent of infected non-human primates recovered after receiving the treatment intravenously 104 to 120 hours after infection. The experimental design differed significantly from the team's earlier work—this time, infected animals were not treated until they developed measurable symptoms of disease.
Ebola virus has been responsible for numerous deaths in Africa over the past several years. In addition to being a global health concern, the virus also is considered a potential biological threat agent.
"By requiring both a documentable fever and a positive diagnostic assay result for Ebola infection before initiating treatment in these animals, we were able to use MB-003 as a true therapeutic countermeasure," said senior author Gene Olinger, Ph.D., of USAMRIID. "These initial results push the threshold of MB-003 from post-exposure prophylaxis to treating verified illness."
According to the scientists, Ebola virus replicates quickly to very high levels, thus overwhelming the host's ability to fight off the infection. MB-003 is a "cocktail" of monoclonal antibodies that help bind to and inactivate the virus. In addition, said Pettitt, the antibodies recognize infected cells and trigger the immune system to kill them off. No side effects of the antibodies were observed in the surviving animals.
MB-003 was developed through a decade-long collaborative effort between private industry and the U.S. government, with funding from the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health (NIH), and the Defense Threat Reduction Agency (DTRA).
"With no vaccines or therapeutics currently licensed to treat or prevent Ebola virus, MB-003 is a promising candidate for continued development," said collaborator Larry Zeitlin, Ph.D., president of Mapp Biopharmaceutical in San Diego, California.
MB-003 is manufactured in a plant-based system by Kentucky BioProcessing in Owensboro, Kentucky. According to Barry Bratcher, the company's chief operating officer, the plant-based system allows for considerable efficacy while KBP's automated facility keeps MB-003 cost-effective and cuts down on the production time required.
"Our facility can produce these proteins in two weeks at a substantial reduction in cost to other production methods," said Bratcher. "This advanced method of manufacturing allows us to address needs quickly and inexpensively."
Zeitlin said Mapp recently announced formation of a joint venture between LeafBio (Mapp's commercialization arm) and Defyrus of Toronto, Canada, to consolidate their antibody programs. He said the relationship will streamline development of the most potent anti-filovirus products.
According to Zeitlin, the next step in the drug development process would be to more extensively test the safety of the antibodies in animals. Once that is established, the safety of the antibodies would need to be assessed in human volunteers. Ultimately, a large efficacy study in non-human primates and a larger safety study in humans would be required for Food and Drug Administration (FDA) licensure of the product.
Explore further: Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
More information: J. Pettitt, L. Zeitlin, D. H. Kim, C. Working, J. C. Johnson, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, M. H. Pauly, K. J. Whaley, M. F. Ingram, A. Zovanyi, M. Heinrich, A. Piper, J. Zelko, G. G. Olinger. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113 (2013)
Medical Xpress on facebook
Related Stories
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
Oct 15, 2012
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.
Scientists identify protective role for antibodies in Ebola vaccine study
Jan 14, 2013
Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.
Post-exposure antibody treatment protects primates from Ebola, Marburg viruses
Mar 13, 2012
Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment ...
Ebola virus uses a protein decoy to subvert the host immune response
Dec 13, 2012
In a study published today in the Open Access journal PLOS Pathogens, researchers at Emory University have discovered a potentially important mechanism by which the Ebola virus alters and evades the immune response of its ...
Scientists reveal how deadly Ebola virus assembles
Aug 15, 2013
Scientists at The Scripps Research Institute (TSRI) have discovered the molecular mechanism by which the deadly Ebola virus assembles, providing potential new drug targets. Surprisingly, the study showed ...
Recommended for you
Rare polio outbreak spreads to Israel's north
3 hours ago
Israel's president is urging the country's children to get polio boosters after a rare outbreak of the virus spread to the north of the country.
New strategy tests for lethal stage of TB in Asia
6 hours ago
More than 20,000 people in Pakistan are being tested for the potentially deadly stage of tuberculosis using a new strategy developed at UC Davis Health System to effectively detect the disease in children for the first time.
Infection during newborn's first week of life associated with bacterial infection in the mother
20 hours ago
Early-onset neonatal infection, defined as infection in the first 7 days of life, is associated with maternal infection and colonization, a systematic review and meta-analysis by Grace Chan (Johns Hopkins School of Public ...
MERS case in Qatar
22 hours ago
Health authorities in Qatar on Tuesday announced the first case of MERS coronavirus in the Gulf state, with a 59-year-old man infected.
Spinal radiosurgery ups risk of vertebral fracture
Aug 20, 2013
(HealthDay)—Vertebral compression fracture (VCF) is a common adverse effect in patients receiving spine stereotactic body radiotherapy (SBRT), according to research published online Aug. 19 in the Journal of ...
Salmonella outbreak linked to NM poultry hatchery
Aug 19, 2013
(AP)—State health officials say a national outbreak of salmonella has been linked to an eastern New Mexico hatchery that sells live baby poultry by mail and supplies them to feed stores.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment